-
Venetoclax, sold
under the
brand names Venclexta and Venclyxto, is a
medication used to
treat adults with
chronic lymphocytic leukemia (CLL),
small lymphocytic...
-
selective inhibitor venetoclax (ABT-199),
which inhibits Bcl-2, but not Bcl-xL or Bcl-w.
Clinical trials studied the
effects of
venetoclax, a BH3-mimetic drug...
- (BCL-2) inhibitor,
venetoclax, plus a CD20
antibody obinutuzumab, OR BTKi (i.e. ibrutinib) plus BCL-2
inhibitor (i.e.
venetoclax) CLL is the most common...
-
juvenile myelomonocytic leukemia. The
combination of
azacitidine and
venetoclax is also
approved for AML.
Azacitidine is a
chemical analogue of the nucleoside...
- variant,
which limits the
effectiveness of first-generation
inhibitors like
venetoclax. "Sonrotoclax - BeiGene". AdisInsight.
Springer Nature Switzerland AG...
- to be one of the most up-regulated (i.e. overactive)
genes in BPDCN.
Venetoclax inhibits the apoptosis-inhibiting
action of BCL-2 and
proved active in...
-
sensitizes acute myeloid leukemia with MLL
rearrangement or NPM1
mutation to
venetoclax". Haematologica. 108 (10): 2837–2843. doi:10.3324/haematol.2022.282160...
- (i.e. DH/THL). RO6870810,
another BET inhibitor, in
combination with
Venetoclax, an
inhibitor of the Bcl-2 protein, is
likewise in a
phase I clinical...
-
about 15-20% of
multiple myeloma patients) may
particularly benefit from
Venetoclax therapy (which is FDA
approved for
other blood cancers but not yet available...
- SY,
Arrate MP,
Chang H,
Gorska AE,
Fuller LD, et al. (February 2020). "
Venetoclax response is
enhanced by
selective inhibitor of
nuclear export compounds...
